Lyell Immunopharma Inc (LYEL) stock saw a decline, ending the day at $0.67 which represents a decrease of $-0.09 or -11.84% from the prior close of $0.76. The stock opened at $0.76 and touched a low ...
Lyell Immunopharma (LYEL) has been on a downward spiral lately with significant selling pressure. After declining 30.9% over the past four weeks, the stock looks well positioned for a trend ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on VYNE Therapeutics (VYNE – Research Report) and Lyell Immunopharma (LYEL – Research Report). Discover ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Lyell Immunopharma (LYEL) “announced initial positive clinical data from the multi-center Phase 1-2 study of IMPT-314 in patients with large B-cell lymphoma that is being presented at the 66th ...